Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Plasmacytoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Dexamethasone 4filanesib 2daratumumab 2Steroids 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Bortezomib 2silmitasertib 1pomalidomide 1milatuzumab 1Proteasome Inhibitors 1Leukapheresis 1CF regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Plasmacytoma × Leukapheresis × Clear all
NCT04665076 2020-12-11

Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors

Hebei Senlang Biotechnology Inc., Ltd.

Phase NA Unknown
60 enrolled
Plasma cell

Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡